BRM therapy for skin malignant tumors and afterward development.Interferon - .GAMMA. therapy for mycosis fungoides.
スポンサーリンク
概要
- 論文の詳細を見る
We have experienced a patient with intractable mycosis fungoides (MF) who has been treated successfully with recombinant human interferon-γ (IFN-γ) for a period of 7 and half years. This therapy was shown to be a safe alternative to other medications with unacceptable side effects and decreasing the dosage of IFN-γ should be done very slowly in order to maintain complete remission.In the early stages of disease, T-and B-cell responses are usually unaltered. However, as the disease progresses, T-cell responses to antigens and mitogens, NK cell activity, lymphokine-activated killer cell (LAK) activity, are known to decrease in association with an increase in levels of immunoglobulins IgE and IgA. Recently the peripheral blood cells of patients with MF were shown to exhibit abnormal production of IL-4, as well as a defect in INF-γ release. IL-4 can antagonize the biological activity of INF-γ and can inhibit the production of this cytokine. This lymphokine secretion pattern may help explain the observed immunologic abnormalities present in advanced disease. Interestingly, IFN-γ antagonizes the biologic activity or IL-4. Thus in the initial stages of MF, IL-4 and IFN-γ may be counteracting a portion of each other's activity. Since the reintroduction of IFN-γ exogenously could patially inhibit the enhanced production of IL-4, leading ultimately to augmented NK cell activity and decreased proliferation of tumor cells, thus, the use of IFN-γ may offer therapeutic benefits to patients with MF.Natural killer cell stimuratory factor (IL-12) is known to induce IFN-γ production by T and NK cells. IL-10 efficiently inhibits a IL-12 production, leading to the decrease in IFN-γ. The reciprocal regulation of these cytokines may result in the abnormal regulation of cellular and humoral immune response in MF. The elucidation of these cytokine interactions will provide highly specific immunotherapeutic approaches to MF.
- 日本皮膚悪性腫瘍学会の論文
著者
関連論文
- 脈絡膜に転移した皮膚悪性黒色腫の1例
- 女性***原発悪性黒色腫における5-S-cysteinyldopaの意義
- 診断クイズ : 忘れがちな疾患15例
- 急性期気道熱傷肺に対する高濃度酸素投与の影響
- 脈絡膜悪性黒色腫12例の臨床病理
- Verruciform Xanthoma
- フランドルテープS(改良品)の皮膚刺激性の検討
- Ki-1 Lymphoma
- 悪性黒色腫におけるIL-2R(interleukin-2 receptor)の発現 : in vivo,in vitroにおける発現とその意義
- 156 アトピー性皮膚炎における好酸球浸潤と接着因子の発現の検討
- WS56. 水疱形成におよぼす好酸球ECPの役割 : 天疱瘡, 類天疱瘡患者の末梢血, 水疱中のECP濃度(IV 好酸球 1990年(2))
- WS17. アトピー性皮膚炎患者における末梢血ECP濃度(I アトピー性皮膚炎 1990年(1))
- 乾癬に対する扁桃摘出術の適応について
- MoAb HMSA-2によるdysplastic melanocyticnevusの免疫組織学的検討
- 悪性黒色腫の生化学的マーカーとしての血清5-S-CD値の評価 (全国66施設の集計: 中間報告)
- 悪性黒色腫の生化学的マーカーとしての血清5-S-CD値の評価(全国66施設の集計 : 中間報告)
- 血清5-S-CDの変動と悪性黒色腫の予後
- 菌状息肉症とインターフェロン-γ療法
- Findings on growth phase fraction of melanocyte tumor by monoclonal anti PCNA antibody.Comparison study on reactivity of clone PC10 and 19A2.
- Effects of TPA, H:7 and OAG on proliferation of human cultured pigment cells and tyrosinase activity.
- BRM therapy for skin malignant tumors and afterward development.Interferon - .GAMMA. therapy for mycosis fungoides.
- BRM療法
- タイトル無し
- Eyeball malignant melanoma : immunohistologic characteristic and prognosis.
- インターフェロンによるICAM-1抗原の発現―培養ヒトメラノーマ細胞と遊離型ICAM-1―
- 悪性黒色腫におけるIL-2R（interleukin-2 receptor）の発現 ―in vivo，in vitroにおける発現とその意義―
- Extranodal non-Hodgkins lymphomaの皮膚浸潤：皮膚原発とWaldeyers ring 原発と思われる2例
- 悪性黒色腫におけるICAM-1（intercellular adhesion molecule-1）の発現―IFN-β投与後のin vivo， in vitroにおける変化―